Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 23 of 110 Updated Nov 17, 2026

Enclomiphene

Androxal · trans-clomiphene

PHASE 3 (NOT APPROVED STANDALONE) · SERM (NON-PEPTIDE)

▓ 153 indexed citations across PubMed (92), ClinicalTrials.gov (31), EuropePMC (30).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

153 citations across 8 tiers

Tap any tier to jump to that section of the bibliography.

Background

Enclomifene (INNTooltip International Nonproprietary Name), or enclomiphene (USANTooltip United States Adopted Name), a nonsteroidal selective estrogen receptor modulator of the triphenylethylene group, acts by antagonizing the estrogen receptor (ER) in the pituitary gland, which reduces negative feedback by estrogen on the hypothalamic-pituitary-gonadal axis, thereby increasing gonadotropin secretion and hence gonadal production of testosterone. It is one of the two stereoisomers of clomifene, which itself is a mixture of 38% zuclomifene and 62% enclomifene. Enclomifene is the (E)-stereoisomer of clomifene, while zuclomifene is the (Z)-stereoisomer. Whereas zuclomifene is more estrogenic, enclomifene is more antiestrogenic. In accordance, unlike enclomifene, zuclomifene is antigonadotropic due to activation of the ER and reduces testosterone levels in men. As such, isomerically pure enclomifene is more favorable than clomifene as a progonadotropin for the treatment of male hypogonadism.

→ Wikipedia

Mechanism of action

Estrogen receptor antagonist at hypothalamus; raises LH/FSH and endogenous testosterone

Researched effects

Testosterone restoration; preserves fertility; raises LH/FSH

Reported efficacy (trial readout)

  • Testosterone Increase 604 ng/dL

    BJU International (Phase 2, 6wk, n=48)

    High confidencen=48Phase 22013

Trial-efficacy data current as of November 16, 2026.

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

12.5-25 mg oral daily

Known concerns

Vision changes; mood changes; headache

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.

    Archives of endocrinology and metabolism · 2025 — META-ANALYSES · AUTHORITY 94.5

  2. Comment on Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.

    Archives of endocrinology and metabolism · 2025 — META-ANALYSES · AUTHORITY 94.5

  3. Response to the letter to the editor: Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.

    Archives of endocrinology and metabolism · 2025 — META-ANALYSES · AUTHORITY 94.5

  4. Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis.

    Andrology · 2023 — META-ANALYSES · AUTHORITY 94.3

  5. Effectiveness of Pharmacological Intervention Among Men with Infertility: A Systematic Review and Network Meta-Analysis.

    2021 — META-ANALYSES · AUTHORITY 94.1

  6. Systematic review of hormone replacement therapy in the infertile man.

    2018 — SYSTEMATIC REVIEWS · AUTHORITY 83.8

  7. Cost-effective Treatment of Unexplained Infertility

    2024 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 77.4

  8. Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS

    2013 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 76.3

  9. Efficacy Study Comparing the Effect of Clomiphencitrate to an Antagonist Protocol

    2013 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 76.3

  10. Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles

    2012 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 76.2

Full citation library

Year distribution

Meta-Analyses

5
  1. 1.

    Hohl A, Chavez MP, Pasqualotto E, Ferreira ROM, et al. · Archives of endocrinology and metabolism · 2025 · PMID 41066380

    This study aimed to evaluate the efficacy and safety of selective estrogen receptor modulators (SERMs), specifically clomiphene and enclomiphene, in treating men with functional hypogonadism. A systematic search was conducted in PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials comparing SERMs with placebo, testosterone (T) gel, or human chorionic gonadotropin (hCG), up to July 2024. The primary endpoints were total testosterone (TT), follicle-stimulat…

  2. 2.

    Tienforti D, Castellini C, Di Giulio F, Totaro M, et al. · Andrology · 2023 · PMID 36604313

    Although selective estrogen receptor modulators have been proposed as a treatment for men with central functional hypogonadism, only a few data have been produced in men with obesity-related functional androgen deficiency. To determine whether and to what extent selective estrogen receptor modulators are an effective and safe therapy in men with obesity-related functional androgen deficiency. A thorough search of PubMed, Web of Science, Scopus, and Cochrane Library databases was performed to ide…

  3. 3.
  4. 4.

    Hohl A, Chavez MP, Pasqualotto E, Ferreira ROM, et al. · Archives of endocrinology and metabolism · 2025 · PMID 41312855

  5. 5.

    Shahid MN, Khan TM, Neoh CF, Lean QY, Bukhsh A, Karuppannan M. · 2021 · PMID 34483894

    <b><i>Background</i>.</b> Infertility is an emerging health issue for men. Comparative efficacy of different pharmacological interventions on male infertility is not clear. The aim of this review is to investigate the efficacy of various pharmacological interventions among men with idiopathic male infertility. All randomized control trials evaluating the effectuality of interventions on male infertility were included for network meta-analysis (NMA) from inception to 31 April 2020, systematically…

Systematic Reviews

1
  1. 6.

    El Meliegy A, Motawi A, El Salam MAA. · 2018 · PMID 29713545

    <h4>Objectives</h4>To highlight alternative treatment options other than exogenous testosterone administration for hypogonadal men with concomitant infertility or who wish to preserve their fertility potential, as testosterone replacement therapy (TRT) inhibits spermatogenesis, representing a problem for hypogonadal men of reproductive age.<h4>Materials and methods</h4>We performed a comprehensive literature review for the years 1978-2017 via PubMed. Also abstracts from major urological/surgical…

Randomised Controlled Trials

3
  1. 7.

    Wiehle RD, Fontenot GK, Wike J, Hsu K, et al. · Fertility and sterility · 2014 · PMID 25044085

    To determine the effect of enclomiphene citrate in men with secondary hypogonadism. Phase II clinical trial. Community dwelling men making visits to physician offices. Men with secondary hypogonadism. Oral administration of enclomiphene citrate or 1% topical T gel. Luteinizing hormone, FSH, T, and semen analysis. Treatment with enclomiphene citrate resulted in increased morning serum T, E2, and LH levels similar to those obtained with a topical T gel in men with secondary hypogonadism. Follicle-…

  2. 8.

    Kim ED, McCullough A, Kaminetsky J · BJU international · 2016 · PMID 26496621

    To determine the effects of daily oral doses of enclomiphene citrate compared with topical testosterone gel treatment on serum total testosterone (TT), luteinising hormone (LH), follicle-stimulating hormone (FSH), and sperm counts in men with secondary hypogonadism. Two parallel randomised, double-blind, double-dummy, placebo-controlled, multicentre, phase III studies were undertaken to evaluate two doses of enclomiphene citrate vs testosterone gel (AndroGel(®) 1.62%) on TT, LH, FSH, and sperm c…

  3. 9.

    Kaminetsky J, Werner M, Fontenot G, Wiehle RD · The journal of sexual medicine · 2013 · PMID 23530575

    Clomiphene citrate is employed off-label in men who have low testosterone and for the restoration of sperm counts in men who have used exogenous testosterone. Clomiphene is a mixture of two diastereoisomers: zuclomiphene and enclomiphene. We evaluated enclomiphene citrate in men with secondary hypogonadism. Our aim was to compare oral enclomiphene citrate as an alternative to topical testosterone. Blood levels of total testosterone (TT), estradiol, follicle-stimulating hormone (FSH), luteinizing…

Clinical Trials

3
  1. 10.

    Miller GD, Moore C, Nair V, Hill B, et al. · The Journal of clinical endocrinology and metabolism · 2019 · PMID 30295816

    Clomiphene is a performance-enhancing drug commonly abused by males in sport, but the extent to which testosterone increases in healthy males following its use is unknown. In addition, evidence suggests that clomiphene, a mixture of cis- and trans-isomers zuclomiphene and enclomiphene, is detectable in urine for months following use; the isomer-specific urinary detection window has yet to be characterized in a controlled study. To determine the effect of once-daily, 30-day clomiphene treatment o…

  2. 11.

    Ghobadi C, Mirhosseini N, Shiran MR, Moghadamnia A, et al. · Journal of clinical pharmacology · 2009 · PMID 19033451

    The pharmacokinetics of the zuclomiphene (Zu) and enclomiphene (En) isomers of clomiphene citrate following a single oral dose (50 mg) were characterized for the first time in patients receiving the drug (ie, infertile women with polycystic ovary syndrome). Plasma concentrations of Zu and En were measured in 9 patients from the second day of their menstrual cycle (day 1 of dosing) up to 21 days. The mean (+/- coefficient of variation) of C(max), t(max), and AUC of Zu was 15 +/- 41 ng/mL, 7 +/- 8…

  3. 12.

    Ghobadi C, Amer S, Lashen H, Lennard MS, et al. · Fertility and sterility · 2009 · PMID 18353317

    To investigate the relationship between the plasma concentrations of clomiphene citrate (CC) isomers zu- (Zu) and enclomiphene (En), and ovulation outcome. Prospective, cohort study. Reproductive medicine and fertility center in a university teaching hospital, United Kingdom. Forty-two women with World Health Organization type 2 infertility. The clinical and biochemical features of patients who were about to start CC for induction of ovulation were recorded. Plasma concentration of Zu and En wer…

Trial Registrations (ClinicalTrials.gov)

31
  1. 13.

    NCT01607320 · NA · Terminated · 2012

    Conditions: Polycystic Ovarian Syndrome

  2. 14.

    NCT06778733 · EARLY_Phase 1 · Completed · 2022

    Conditions: Female Infertility

  3. 15.

    NCT03674385 · Phase 2 · Completed · 2018

    Conditions: Clomiphene Citrate Resistant Polycystic Ovary Syndrome

  4. 16.

    NCT00911313 · NA · Completed · 2006

    Conditions: Polycystic Ovary Syndrome

  5. 17.

    NCT02520505 · NA · Withdrawn · 2015

    Conditions: Endometriosis, Infertility

  6. 18.

    NCT07419776 · Completed · 2023

    Conditions: Poly Cystic Ovary Syndrome

  7. 19.

    NCT01044862 · Phase 3 · Completed · 2010

    Conditions: Pregnancy, Unexplained Infertility

  8. 20.

    NCT03566225 · EARLY_Phase 1 · Completed · 2018

    Conditions: Pioglitazone

  9. 21.

    NCT06813118 · Phase 1 · Completed · 2024

    Conditions: Polycystic Ovarian Syndrome

  10. 22.

    NCT01532414 · Phase 3 · Completed · 2012

    Conditions: Secondary Hypogonadism

  11. 23.

    NCT05075863 · NA · Completed · 2021

    Conditions: Polycystic Ovary Syndrome

  12. 24.

    NCT00501839 · Phase 4 · Withdrawn · 2008

    Conditions: Polycystic Ovary Syndrome, Infertility

  13. 25.

    NCT03681197 · EARLY_Phase 1 · Unknown · 2018

    Conditions: Infertility

  14. 26.

    NCT01856062 · Phase 4 · Unknown · 2013

    Conditions: Infertility

  15. 27.
  16. 28.

    NCT06934785 · NA · Recruiting · 2025

    Conditions: Letrozole, Clomiphene Citrate, Ovulation Disorder (+1)

  17. 29.

    NCT02274311 · Phase 2 · Completed · 2011

    Conditions: Acromegaly

  18. 30.

    NCT03615547 · Phase 3 · Not Yet Recruiting · 2026

    Conditions: Azoospermia, Nonobstructive

  19. 31.

    NCT01791751 · Phase 4 · Completed · 2012

    Conditions: Female Infertility

  20. 32.

    NCT02186782 · Phase 4 · Unknown · 2014

    Conditions: Infertility, Anovulation

  21. 33.
  22. 34.

    NCT05846906 · Phase 2/Phase 3 · Completed · 2021

    Conditions: Infertility, Female

  23. 35.

    NCT06178523 · Phase 4 · Completed · 2024

    Conditions: Unexplained Infertility

  24. 36.

    NCT03028532 · Phase 1 · Completed · 2017

    Conditions: Sports Drug Abuse, Abuse of Steroids or Hormones

  25. 37.

    NCT01718444 · NA · Terminated · 2015

    Conditions: Polycystic Ovary Syndrome, Infertility

  26. 38.

    NCT00461643 · Phase 4 · Unknown · 2007

    Conditions: Anovulatory Infertility Related to Polycystic Ovary Syndrome

  27. 39.

    NCT02352597 · Phase 4 · Completed · 2013

    Conditions: Polycystic Ovaries

  28. 40.
  29. 41.

    NCT04331197 · Phase 4 · Unknown · 2020

    Conditions: Subfertility

  30. 42.

    NCT01577472 · Phase 4 · Completed · 2013

    Conditions: Female Infertility, Ovarian Insufficiency

  31. 43.

    NCT00835744 · Phase 4 · Completed · 2008

    Conditions: Infertility

Reviews

4
  1. 44.

    Hill S, Arutchelvam V, Quinton R · IDrugs : the investigational drugs journal · 2009 · PMID 19204885

    Enclomiphene (Androxal), in development by Repros Therapeutics Inc, is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes. Enclomiphene constitutes the trans-stereoisomer of clomiphene citrate, a drug that has been widely prescribed for several decades for the treatment of female ovulatory dysfunction. Because of the antagonistic effects of enclomiphene, the drug has the potential to increase serum testosterone levels in men wit…

  2. 45.

    Rodriguez KM, Pastuszak AW, Lipshultz LI · Expert opinion on pharmacotherapy · 2016 · PMID 27337642

    Hypogonadism is a growing concern in an aging male population. Historically treated using exogenous testosterone, concerns about possible adverse effects of testosterone have led physicians to seek alternative treatment approaches. Enclomiphene citrate is the trans isomer of clomiphene citrate, a non-steroidal estrogen receptor antagonist that is FDA-approved for the treatment of ovarian dysfunction in women. Clomiphene citrate has also been used off-label for many years to treat secondary male…

  3. 46.

    Hochu G, Geyer-Kim I, Kim E · Translational andrology and urology · 2025 · PMID 41522318

    The rising prevalence of testosterone deficiency has led to increased use of exogenous testosterone therapy, including among men desiring fertility. Conventional testosterone replacement therapies (TRT) restore serum testosterone but suppress gonadotropins, resulting in impaired spermatogenesis. Consequently, newer approaches aim to normalize testosterone levels while preserving fertility potential. Intranasal testosterone provides short-acting, pulsatile testosterone delivery that mimics physio…

  4. 47.

    Achua JK, Frech FS, Ramasamy R · Current opinion in endocrinology, diabetes, and obesity · 2020 · PMID 33003069

    In this review, we outline the most recent advances in the development of Leydig stem cells (LSCs) and summarize the current and upcoming treatments for hypogonadism. In-vitro and in-vivo studies show that inducing stem cells to differentiate into testosterone-producing adult Leydig cells is possible. In addition, LSCs can be grafted with Sertoli cells to increase testosterone levels in vivo. This therapy causes minimal effects on luteinizing hormone and follicle stimulating hormone levels. Nove…

Research Articles

105
  1. 48.

    Saffati G, Kassab J, Orozco Rendon D, Hinojosa-Gonzalez DE, et al. · Translational andrology and urology · 2024 · PMID 39434750

    Both clomiphene citrate and its isomer, enclomiphene, have become widespread within urologic practice; thus, understanding these medications' comparative benefits and risks is crucial for optimizing treatment and providing improved therapeutic options. We sought to investigate the longitudinal benefits and risks associated with enclomiphene, compared to clomiphene, and to provide valuable insights for clinicians when making treatment decisions in the management of hypogonadism. We retrospectivel…

  2. 49.

    Thomas J, Suarez Arbelaez MC, Narasimman M, Weber AR, et al. · Cureus · 2023 · PMID 37546076

    Introduction Infertility and hypogonadism in males can greatly affect their reproductive health and overall well-being. Since exogenous testosterone administration for hypogonadism management may disrupt the normal hormonal cascade necessary for spermatogenesis, clomiphene citrate (CC) and enclomiphene citrate (EC) are medications often used to manage hypogonadism and male infertility. This study aims to directly compare the effects of CC and EC on serum testosterone levels and semen parameters…

  3. 50.

    Franz-Odendaal TA, Bezuhly M · Plastic surgery (Oakville, Ont.) · 2023 · PMID 37915340

  4. 51.

    Earl JA, Kim ED · Expert review of endocrinology & metabolism · 2019 · PMID 31063005

    Hypogonadism is an important issue among the male population. Treatments such as exogenous testosterone have become very popular. One of the adverse effects of testosterone is its suppression of fertility. This has lead to the use of alternative therapies such as selective estrogen receptor modulators (SERMs) that aim to correct hypogonadism without reducing fertility. Areas covered: The SERM, clomiphene citrate, which is approved by the FDA for the treatment of ovarian dysfunction, has been sho…

  5. 52.

    Wiehle R, Cunningham GR, Pitteloud N, Wike J, et al. · BJU international · 2013 · PMID 23875626

    To determine the pharmacodynamic (PD) profile of serum total testosterone levels (TT) and luteinizing hormone (LH) in men with secondary hypogonadism following initial and chronic daily oral doses of enclomiphene citrate in comparison to transdermal testosterone. To determine the effects of daily oral doses of enclomiphene citrate (Androxal®) in comparison to transdermal testosterone on other hormones and markers in men with secondary hypogonadism. This was a randomized, single blind, two-center…

  6. 53.

    Young SL, Opsahl MS, Fritz MA · Fertility and sterility · 1999 · PMID 10202872

    To determine the serum concentrations of enclomiphene and zuclomiphene across consecutive cycles of clomiphene citrate treatment in anovulatory infertile women. Prospective cohort. Tertiary institutional infertility clinic. Fourteen consenting anovulatory infertile women receiving standardized, cyclic, incremental treatment with clomiphene citrate for ovulation induction. Clomiphene citrate treatment (50-150 mg/d, cycle days 5-9), titrated to the minimum effective ovulation-inducing dose, was ad…

  7. 54.

    Ghobadi C, Gregory A, Crewe HK, Rostami-Hodjegan A, et al. · Drug metabolism and pharmacokinetics · 2008 · PMID 18445989

    Clomiphene is a first line treatment for anovulation, a common cause of infertility. Response to clomiphene is variable and unpredictable. Tamoxifen is structurally related to clomiphene, and also shows considerable variation in response. CYP2D6 and CYP3A4 are major contributors to the metabolism of tamoxifen. The aim of the present work was to define the role of CYP2D6 and CYP3A4 in the in vitro metabolism of enclomiphene, regarded by some as the more active isomer of clomiphene. Enclomiphene (…

  8. 55.

    Schramm RD, Roberge S, Reeves JJ · Journal of animal science · 1991 · PMID 1778825

    The objective of this study was to determine whether an antiestrogen (enclomiphene) would shorten the interval to first estrus and conception in postpartum beef cows. Sixty postpartum Angus beef cows were stratified by age, body condition, and calving date and were randomly assigned to one of two treatment groups. Group 1 cows (n = 24) received three silastic implants, each containing 150 mg of enclomiphene, on d 20 postpartum. Implants were removed on d 30 postpartum. Group 2 cows (n = 28), rec…

  9. 56.

    Kaminetsky J, Hemani ML · Expert opinion on investigational drugs · 2009 · PMID 19938905

    Hypogonadism has a number of important clinical consequences related to androgen deficiency and impaired spermatogenesis. The cause of this condition is multifactorial and can result from hypothalamic, pituitary or gonadal dysfunction as well as factors that affect hormonal signaling along the hypothalamic-pituitary-gonadal axis. While testosterone replacement is the most common treatment, it can paradoxically lead to infertility, and may be a less physiologic therapy for patients with secondary…

  10. 57.

    Murphy LC, Sutherland RL · The Journal of clinical endocrinology and metabolism · 1983 · PMID 6408114

    The antitumor activity of three enclomiphene (trans-1- (p-beta-diethylaminoethoxyphenyl)1,2-diphenyl-2-chloroethylene) analogs and the cis isomer zuclomiphene was investigated in MCF 7 human mammary carcinoma cells in culture. Relative antitumor activity was compared with relative binding affinities (RBAs) for the nuclear estrogen receptor (RE; estradiol = 100%) and a microsomal antiestrogen-binding site (AEBS; tamoxifen = 100%) measured in cell-free extracts from MCF 7 cells. Modifications in t…

  11. 58.

    Opsahl MS, Fitz TA, Rexroad CE, Fritz MA · Human reproduction (Oxford, England) · 1996 · PMID 8671435

    We examined the effects of enclomiphene and zuclomiphene, alone and in combination with oestradiol, on basal and gonadotrophin-stimulated progesterone secretion by isolated subpopulations of both large (granulosa-lutein) and small (theca-lutein) ovine luteal cells. Isolated large and small luteal cells derived from intact, enucleated ovine corpora lutea were incubated for 48-120 h with or without 22R-hydroxycholesterol or pregnenolone (2.5 microM) and a range of enclomiphene, zuclomiphene, and/o…

  12. 59.

    Foster J, Choo L, Patel A, Kirby M, et al. · The world journal of men's health · 2026 · PMID 41714894

  13. 60.

    Helo S, Mahon J, Ellen J, Wiehle R, et al. · BJU international · 2017 · PMID 27511863

    To determine the relative concentrations of enclomiphene (ENC) and zuclomiphene (ZUC) isomers in men with hypogonadism on long-term clomiphene citrate (CC) therapy, and to determine whether patient age, body mass index (BMI) or duration of therapy were predictive of relative concentrations of ENC and ZUC. Men already receiving CC 25 mg daily therapy for secondary hypogonadism for a minimum of 6 weeks were recruited to have their ENC and ZUC levels assessed. Total testosterone, free testosterone,…

  14. 61.

    Joseph T, Gibbs LM, Pham K · The Journal of family practice · 2022 · PMID 35259334

    YES. For both normal-weight and obese men with low testosterone levels and hypogonadal symptoms, selective estrogen receptor modulators (SERMs), such as clomiphene citrate (CC) and enclomiphene citrate (EC), appear to be effective and safe for improving serum testosterone levels (strength of recommendation [SOR]: C, disease-oriented outcomes from randomized controlled trials [RCTs] and cohort studies). Studies also show that symptom improvement is comparable to that with exogenous testosterone r…

  15. 62.

    Chang CF, Reeves JJ · Journal of animal science · 1987 · PMID 3112086

    This study was designed to determine whether an anti-estrogen can block the negative effect of estrogens on luteinizing hormone (LH) release and therefore decrease the postpartum interval in suckled beef cows. In Exp. I, eight suckled postpartum beef cows were randomly assigned to treatment and control groups. Treatment cows received 1 g/d clomiphene citrate (im) from d 21 to 28 postpartum, while control cows were injected with saline. On d 28 postpartum, there was no difference (P greater than…

  16. 63.

    Kovac JR · Nature reviews. Urology · 2016 · PMID 26787395

  17. 64.

    Schmidt GE, Kim MH, Mansour R, Torello L, et al. · American journal of obstetrics and gynecology · 1986 · PMID 3083679

    The ovulatory agent clomiphene citrate, a racemic mixture of the estrogenic zuclomiphene and antiestrogenic enclomiphene isomers, has been associated with gamete/embryo toxicity in various animal models. To assess the potential effects of these isomers on fertilization and early embryogenesis, 3200 embryos were obtained from mouse oocytes fertilized in vivo and in vitro and exposed to increasing concentrations of zuclomiphene, enclomiphene, and clomiphene citrate in culture. Fertilization rates…

  18. 65.
  19. 66.

    Huang ES, Miller WL · Endocrinology · 1983 · PMID 6401242

    17 beta-Estradiol (E2) alters gonadotropin secretions in ovine pituitary cell cultures by 1) augmenting the LH response to LHRH and 2) inhibiting the basal secretion of FSH. These responses were used to study the estrogenic and antiestrogenic effects of enclomiphene, zuclomiphene, and their commercial mixture, Clomid. In terms of the LH response to LHRH, Clomid and enclomiphene (10(-6) M) acted as E2 antagonists because they blocked the action of E2 (10(-10) M). By themselves they did not alter…

  20. 67.

    Turner RT, Evans GL, Sluka JP, Adrian MD, et al. · Endocrinology · 1998 · PMID 9724022

    The substituted triphenylethylene antiestrogen clomiphene (CLO) prevents cancellous bone loss in ovariectomized (OVX'd) rats. However, CLO is a mixture of two stereoisomers, enclomiphene (ENC) and zuclomiphene (ZUC), which have distinctly different activities on reproductive tissues and tumor cells. The purpose of the present dose response study was to determine the effects of ENC and ZUC on nonreproductive estrogen target tissues. These studies were performed in 7-month-old female rats with mod…

  21. 68.

    Fontenot GK, Wiehle RD, Podolski JS · BJU international · 2016 · PMID 26220499

    To determine, in a chronic dosing study, the oral toxicity potential of the test substances, enclomiphene citrate (ENC) and zuclomiphene citrate (ZUC), when administered to male mice by oral gavage. Mice were divided into five treatment groups. Group I, placebo; Group II, 40 mg/kg body weight/day ENC; Group III, 4 mg/kg/day ENC; Group IV, 40 mg/kg/day ZUC; Group V, 4 mg/kg/day ZUC. Serum samples and tissues were obtained from each mouse for analysis and body weights were measured. In this chroni…

  22. 69.

    Sasson S, Notides AC · The Journal of biological chemistry · 1982 · PMID 7118895

    The calf uterine estrogen receptor showed positive cooperativity of [3H]estradiol equilibrium binding; the Scatchard plot was convex and the Hill coefficient was 1.69 +/- 0.021 (n = 14). The effects of the estrogenic antagonists, zuclomiphene (cis-2-(p-[2-chloro-1,2-diphenylvinyl]phenoxy)triethylamine citrate) and enclomiphene (trans-23-(p-[2-chloro-1,2-diphenylvinyl]phenoxy)triethylamine citrate), on the positive cooperativity of [3H]estradiol binding were measured by titrating the receptor wit…

  23. 70.

    Gregg DW, Nett TM · Journal of animal science · 1990 · PMID 2123847

    Experiments were conducted to characterize the ability of the antiestrogen enclomiphene (ENC) to block the effects of estradiol on secretion of LH in ovariectomized ewes. To determine whether ENC could block an estradiol-induced LH surge, ewes (n = 4/group) were administered 10 to 250 mg ENC followed 30 min later by 25 micrograms estradiol. Ten or 25 mg ENC suppressed the estradiol-induced LH surge in one of four ewes, whereas 100- or 250-mg doses suppressed the LH surge in three and four of fou…

  24. 71.
  25. 72.
  26. 73.

    Still JG, Greiss FC · Gynecologic investigation · 1976 · PMID 992480

    Changes in the left uterine artery blood flow (YBF) after intraarterial administration of estradiol-17beta and cis- and trans-clomiphene citrate to conscious, oophorectomized ewes were monitored by chronically implanted electromagnetic flow probes. Cis-clomiphene produced UBF increases comparable to or greater than those produced by estradiol-17beta but at dose levels 20 times greater. Comparison of UBF response curves for cis-clomiphene with those for estradiol-17beta showed a delayed onset of…

  27. 74.

    Sengupta A, Hage DS · Analytical chemistry · 1999 · PMID 10489529

    This study used high-performance affinity chromatography (HPAC) and immobilized human serum albumin (HSA) columns to examine the specificity and cross-reactivity of various compounds that have been proposed as markers for the minor binding sites of HSA. These agents included acetyldigitoxin and digitoxin as probes for the digitoxin site, phenol red as a probe for the bilirubin site, and cisor trans-clomiphene as markers for the tamoxifen site. None of these probes showed any significant binding…

  28. 75.

    Trubert J, Garda MR, Matkovska L, Gauthier S, et al. · Molecular pharmaceutics · 2025 · PMID 41071236

    Amorphous states of clomiphene trans/cis isomers (namely, enclomiphene and zuclomiphene) were isolated by melt cooling procedures. Despite relatively close

  29. 76.

    Nelson EA, Barnes AB, Wiehle RD, Fontenot GK, et al. · Viruses · 2016 · PMID 27490565

    The 2014 outbreak of Ebola virus (EBOV) in Western Africa highlighted the need for anti-EBOV therapeutics. Clomiphene is a U.S. Food and Drug Administration (FDA)-approved drug that blocks EBOV entry and infection in cells and significantly protects EBOV-challenged mice. As provided, clomiphene is, approximately, a 60:40 mixture of two stereoisomers, enclomiphene and zuclomiphene. The pharmacokinetic properties of the two isomers vary, but both accumulate in the eye and male reproductive tract,…

  30. 77.

    Ross JW, Paup DC, Brant-Zawadzki M, Marshall JR, et al. · Endocrinology · 1973 · PMID 4721294

  31. 78.
  32. 79.

    Westfahl PK · Experientia · 1989 · PMID 2492231

    The effect of two antiestrogens, enclomiphene and tamoxifen, on luteal function in the guinea pig was compared to that of estradiol, a known luteolysin. Enclomiphene caused premature luteolysis when administered during the early or mid-luteal phase of the cycle, but was not as potent as estradiol. Tamoxifen had no effect. The luteolytic effect of enclomiphene was mediated by the uterus, as has been shown for estradiol.

  33. 80.

    Marth C, Daxenbichler G, Buehring GC, Hofstädter F, et al. · Biochemical pharmacology · 1984 · PMID 6439216

    The growth effects of tamoxifen (T), desmethyl-tamoxifen (dMeT), 4-hydroxy-tamoxifen (OHT) and enclomiphene (Clo) on cultured human breast cancer cell lines have been related to published binding affinities for the estrogen receptor. Only in cells which were stimulated by estrogens did these anti-estrogens markedly inhibit growth. In both estrogen sensitive cell lines tested, 734 B and ZR 75.1, the anti-estrogen activity showed the identical rank: OHT much greater than Clo approximately equal to…

  34. 81.

    Kneussl ES, Ances IG, Albrecht ED · American journal of obstetrics and gynecology · 1982 · PMID 7148904

    Administration of the antiestrogen ethamoxytriphetol (MER-25) during baboon gestation results in a marked decline in placental progesterone production. Since this effect in primates may be modulated via an estrogen receptor, the present study investigated the possible existence of an estrogen receptor in human placenta. Villous tissue of human, term placentas was homogenized in 0.01M Tris-HCl, ethylenediaminetetraacetic acid, dithiothreitol, glycerol buffer. Cytosol was incubated with 10(-8)M [3…

  35. 82.

    Ruenitz PC · Drug metabolism and disposition: the biological fate of chemicals · 1981 · PMID 6117445

    Metabolism of the triarylethylene antiestrogen enclomiphene (EC) has been studied in rabbit liver. Incubation of EC with microsomes in the presence of NADPH gave two metabolites, EC-1 and EC-2, as determined by thin-layer chromatography (TLC). EC-1 had mass-spectral features that were identical to those of synthetic desethylenclomiphene, and was indistinguishable from this compound by TLC and gas-liquid chromatography (GLC). EC-2 was similarly identical to synthetic 4-hydroxyclomiphene, but was…

  36. 83.

    Wang C, Erickson GF, Hopper B, Bsueh AJ · Biology of reproduction · 1980 · PMID 6248140

  37. 84.

    Bitonti AJ, Baumann RJ, Bush TL, Cashman EA, et al. · Anticancer research · 1996 · PMID 8917350

    MDL 103,323, an enclomiphene analog, was tested for binding to the estrogen receptor, inhibition of human tumor xenografts and prevention of carcinogen-induced mammary tumors. MDL 103,323 had 5-6 fold greater affinity for the human estrogen receptor than did either tamoxifen or enclomiphene. Consistent with enhanced binding affinity, MDL 103,323 was more potent against MCF-7 cell proliferation and MCF-7 xenografts in nude mice were inhibited almost completely by MDL 103,323 doses > or = 0.02 mg/…

  38. 85.

    Wing LY, Hammond JO, Brodie AM · Endocrinology · 1988 · PMID 3131115

    4-Hydroxyandrostene-3,17-dione (4-OHA) inhibits ovarian aromatase activity and causes regression of carcinogen-induced hormone-dependent mammary tumors in rats. Although estrogen levels were reduced, LH levels did not increase nor did uterine weight decline in 4-OHA-treated animals. These findings are in contrast to those in animals deprived of estrogen by ovariectomy. The possible direct action of 4-OHA on gonadotropin secretion and uterine growth was, therefore, investigated in ovariectomized…

  39. 86.

    Warren S · Cureus · 2026 · PMID 42170362

    Background Declining testosterone levels in adult males represent a significant clinical burden. Conventional testosterone replacement therapy (TRT) with exogenous androgens suppresses the hypothalamic-pituitary-gonadal (HPG) axis, causes testicular atrophy, and impairs spermatogenesis, outcomes that are unacceptable for many patients. Enclomiphene citrate, a selective estrogen receptor modulator (SERM), stimulates endogenous gonadotropin release and has been studied as an alternative to exogeno…

  40. 87.

    Olsson JH, Nilsson L, Hillensjö T · Human reproduction (Oxford, England) · 1987 · PMID 3117835

    The effect of en-clomiphene and zu-clomiphene (10(-9)-10(-5) M) on progestin synthesis in cultured human granulosa cells was studied under basal conditions and in the presence of LH (100 ng/ml). Granulosa cells were obtained from either pre-ovulatory follicles of clomiphene-HMG-stimulated cycles or from large follicles of mid-to-late follicular phase of spontaneous cycles. The basal and LH-stimulated progesterone accumulation was dose-dependently reduced by en- and zu-clomiphene (10(-6)-10(-5) M…

  41. 88.

    Hage DS, Sengupta A · Analytical chemistry · 1998 · PMID 9823719

    High-performance affinity chromatography and zonal elution studies were used to examine the binding that takes place between the drug clomiphene and the protein human serum albumin (HSA). Equations were derived to describe the behavior of zonal elution experiments in which a solubilizing agent is present in the mobile phase to aid in the dissolution of a competing agent or injected analyte. These equations were then used to determine the association equilibrium constants for the clomiphene/HSA s…

  42. 89.

    Teramoto S, Kato O · Reproductive biomedicine online · 2007 · PMID 17697488

    Enclomiphene, an isomeric component of clomiphene citrate, acts antagonistically to the oestradiol receptor at the hypothalamus level, inhibiting both negative and positive feedback, and resulting in the induction of ovarian stimulation and suppression of ovulation. The minimal ovarian stimulation protocol takes full advantage of these characteristics of clomiphene citrate. Administration of 50 mg clomiphene citrate is initiated on cycle day 3, and from day 8 patients receive 150 IU of FSH every…

  43. 90.

    Clark JH, Guthrie SC · Journal of steroid biochemistry · 1983 · PMID 6406767

    The ability of clomiphene and its isomers to cause estrogenic responses during the neonatal period in the rat was examined. Rats were injected s.c. with clomiphene (CL), zuclomiphene (ZUC) or enclomiphene (ENC) on days 1,3, and 5 of life and the stimulation of the reproductive tract and estrogen receptor binding was observed. Uterine weight and DNA content were increased significantly by day 7 in animals treated with clomiphene or zuclomiphene. Uterine epithelial hypertrophy was present in all g…

  44. 91.

    Olsson JH, Granberg S · Human reproduction (Oxford, England) · 1990 · PMID 2081804

    The effects of en-clomiphene and zu-clomiphene (10(-7) - 10(-5) M) on oestradiol synthesis in human granulosa cells were studied. Granulosa cells were obtained from stimulated cycles in women undergoing oocyte retrieval, in the course of in-vitro fertilization/embryo transfer due to mechanical infertility. En-clomiphene and zu-clomiphene (10(-5) M) significantly reduced basal and LH-stimulated oestradiol synthesis after 2-4 days of culture. The LH-stimulated synthesis was also significantly and…

  45. 92.

    Clark JH, Mitchell WC, Guthrie SC · Journal of steroid biochemistry · 1987 · PMID 3586657

    The relative binding affinities (RBA) of various compounds for the triphenylethylene antiestrogen binding sites (TABS) were examined. The ability of tamoxifen to inhibit the binding of [3H]tamoxifen to salt extracted (0.4 M KCl) TABS from rat liver nuclei was used as a standard by which other compounds were compared (tamoxifen RBA, 100; Kd approximately 1 nM). Nafoxidine was the most effective triphenylethylene compound used (RBA 333; Kd approximately 0.3 nM) whereas the RBA of zuclomiphene and…

  46. 93.

    Bowman SP, Leake A, Morris ID · The Journal of endocrinology · 1981 · PMID 6783718

    The temporal effects of the oestrogen antagonist en-clomiphene were studied in the 3 week ovariectomized rat for up to 24 days after a single dose of 0.5 or 50 mg/kg. Cytosol binding of [3H]oestradiol was measured in central and peripheral target tissues. One day after treatment both doses of en-clomiphene decreased binding of [3H]oestradiol to similar levels within tissues. In brain cytosols binding of [3H]oestradiol returned to expected control values by 16 days with the exception of the hypot…

  47. 94.

    Weissenberg R, Dar Y, Lunenfeld B · Andrologia · 1992 · PMID 1503253

    The effect of clomiphene citrate (CC) and of its Zuclomiphene (ZuC) and Enclomiphene (EnC) isomers on the reproductive organs of immature male rats under different experimental conditions is reported. CC, ZuC, and EnC were administered daily to groups of either intact or castrated rats between the age of 21-44 d. This led to inhibition of weight increase of testis and accessory glands in the intact group. Spermatogenesis was arrested at the stage of primary spermatocyte following CC and ZuC trea…

  48. 95.

    Souma JA, Marshall LD, Abdul-Karim RW · Toxicology and applied pharmacology · 1972 · PMID 5074580

  49. 96.

    Ramsey RB, Fischer VW · Acta neuropathologica · 1976 · PMID 61699

    Developing rats were injected intraperitoneally twice weekly with a combination of two hypocholesterolemic agents: trans-clomiphene 50 mg per kg body weight, and AY-9944, 5 mg per kg body weight. Treatment was initiated at 5 days of age. Biochemical and electron microscopic examination was carried out on animals sacrificed at 20 days of age. Only rarely were cytoplasmic inclusion bodies seen in the CNS. Biochemical analysis of the brain and spinal cords of treated animals indicated the abnormal…

  50. 97.

    Pakrasi PL, Tiwari A · Life sciences · 2006 · PMID 16934298

    The ovulation induction property of ICI 182,780 a pure antiestrogen and enclomiphene citrate (ENC) was carried out in Scotophilus heathi, an Indian tropical vespertillionid bat, during December to February i.e., preovulatory period. This bat ovulates two ova naturally and shows ovulatory asynchrony. The study showed that 100 ìg of ENC followed by 10 IU hCG resulted in significantly lower number of ovulation. Whereas, the pure antiestrogen ICI 182,780 at a dose of 100 ìg followed by 10 IU hCG res…

  51. 98.

    Richards JF, Griffith DR · Fertility and sterility · 1974 · PMID 4810202

  52. 99.

    Jordan VC, Gottardis MM, Satyaswaroop PG · Annals of the New York Academy of Sciences · 1991 · PMID 1905895

    An estrogen receptor and progesterone receptor positive endometrial carcinoma (EnCa101) will grow in response to either estradiol or tamoxifen when transplanted into athymic mice. We have tested several antiestrogens with different properties to determine their ability to support endometrial tumor growth. Trioxifene, enclomiphene and nafoxidine are all as active as tamoxifen whereas the antiestrogen keoxifene, that has reduced estrogen-like properties, will partially inhibit tamoxifen-stimulated…

  53. 100.

    Crewe HK, Ghobadi C, Gregory A, Rostami-Hodjegan A, et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2007 · PMID 17085084

    A rapid, sensitive and selective LC-MS method is described for the simultaneous determination of zuclomiphene and enclomiphene in plasma from patients undergoing treatment with clomiphene citrate for the induction of ovulation. Samples spiked with N-didesmethyltamoxifen, the internal standard, were extracted into methyl tertiary butyl ether. The compounds were separated on a Luna C(18) analytical column, and a mobile phase of methanol-water (70:30 v/v) containing 0.05% trifluoroacetic acid at a…

  54. 101.

    Burghardt RC, Gaddy-Kurten D, Burghardt RL, Kurten RC, et al. · Biology of reproduction · 1987 · PMID 3593845

    A number of steroidal and nonsteroidal estrogen receptor-binding ligands were tested for their ability to affect the formation and internalization of gap junctions in hypophysectomized rat uterine myometrial and serosal cells. Potent estrogen, including diethylstilbestrol, estradiol benzoate (EB), estradiol-17 beta, and the weak estrogens, estriol and estrone, stimulate formation of macular and annular gap junctions in myometrium in a dose-dependent fashion when administered in daily injections…

  55. 102.

    Bempong DK, Honigberg IL · Journal of pharmaceutical and biomedical analysis · 1996 · PMID 8933425

    Plackett-Burman (P-B) experimental design has been used to optimize the factors affecting separation of Z and E isomers of clomiphene (zuclomiphene and enclomiphene respectively) using capillary electrophoresis. The P-B design was used to simultaneously investigate the following five factors: buffer ionic strength, buffer pH, heptakis (2,3,6-tri-o-methyl) beta-cyclodextrin (TMCD) concentration, methanol concentration and injection time, each at three levels. In addition to these, a dummy variabl…

  56. 103.

    Burghardt RC, Mitchell PA, Kurten R · Biology of reproduction · 1984 · PMID 6421335

    The ability of several triphenylethylene antiestrogens to affect the modulation of gap junctions in rat uterine myometrial and serosal cells was examined in animals 60 days following hypophysectomy. Five daily injections of enclomiphene, zuclomiphene, tamoxifen, nafoxidine, CI 628 or CI 680 (500 micrograms per injection) promote uterine luminal epithelial cell hypertrophy characteristic of exogenous estrogen administration. These same compounds, however, fail to induce myometrial cell or increas…

  57. 104.

    Bowman SP, Leake A, Miller M, Morris ID · The Journal of endocrinology · 1981 · PMID 6783716

    The oestrogen agonist and antagonist activity of a single dose of en-clomiphene (0.5--50 mg/kg) was studied in peripheral and brain tissue in the 3 week ovariectomized rat. 17 beta-Oestradiol benzoate (100 microgram/kg) or vehicle was injected 24 h after en-clomiphene administration and data collected at 72 h. En-clomiphene produced a dose-related (agonist) fall in body weight and food intake. Agonist action was not observed upon sexual receptivity and prolactin secretion; oestrogen antagonism o…

  58. 105.

    Racowsky C, Baldwin KV · Journal of reproduction and fertility · 1989 · PMID 2600898

    Mature antral follicles were collected from PMSG-primed hamsters before the LH surge on Day 4 of the oestrous cycle and were incubated individually for 6 or 10 h under 95% O2 and 5% CO2. The relationship between follicle size and follicular fluid volume was established, and both the oestradiol output during incubation and the LH sensitivity of the follicle with respect to induction of meiotic resumption were determined. The data obtained from these initial studies were then applied to experiment…

  59. 106.

    Murthy US, Adiga PR · Biochimica et biophysica acta · 1978 · PMID 620073

    The kinetics of estrogen-induced elevation in the plasma concentration of riboflavin-binding protein, a minor yolk constituent, was investigated in immature male chicks, using a specific and sensitive radioimmunoassay procedure. Following a single injection of the hormone, the plasma riboflavin-binding protein content was enhanced several-fold at 6 h, reaching peak levels around 48 h and declining thereafter. A two-fold amplification of the response was evident on secondary stimulation with the…

  60. 107.

    Maertens C, Droogmans G, Chakraborty P, Nilius B · British journal of pharmacology · 2001 · PMID 11156570

    1. We have used the whole-cell patch clamp technique to study the effect of the partial anti-oestrogens clomiphene and nafoxidine, the pure anti-oestrogens ICI 182,780 and RU 58,668 and the oestrogen ss-estradiol, on the volume-regulated anion channel (VRAC) in cultured pulmonary artery endothelial (CPAE) cells. 2. In contrast to the pure anti-oestrogens and ss-estradiol, clomiphene and nafoxidine potently inhibited the volume-sensitive chloride current, I(Cl,swell), activated by challenging CPA…

  61. 108.

    Fritz MA, Holmes RT, Keenan EJ · American journal of obstetrics and gynecology · 1991 · PMID 1906682

    A direct adverse effect of clomiphene citrate on the endometrium has been presumed, and interference with estrogen receptor-mediated endometrial estrogen receptor and progesterone receptor induction has been implicated as the mechanism responsible for an increased incidence of luteal phase deficiency in association with clomiphene citrate treatment. To clarify the net influence of clomiphene administration on endometrial steroid receptor induction, we studied five normal ovulatory women, in both…

  62. 109.
  63. 110.

    Ghraf R, Schneider K, Kirchhoff J, Hiemke C · Journal of neurochemistry · 1982 · PMID 6950028

    Gonadectomy of male rats led to a threefold increase of 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSDH) activity in pituitary homogenates that could be completely reversed by chronic administration of estradiol or 5 alpha-dihydrotestosterone (DHT). 3 alpha-HSDH was found to be distributed mainly between the 10,000 g and 100,000 g sediments from whole homogenates. The microsomal enzyme activity showed a substantial specificity for NADH whereas the cytosolic enzyme (100,000 g supernatant) demo…

  64. 111.

    Maheshwari A, Saraswat H, Upadhyay SK · Chirality · 2017 · PMID 28644553

    A major challenge in pharmaceuticals for clinical applications is to alter the solubility, stability, and toxicity of drug molecules in living systems. Cyclodextrins (CDs) have the ability to form host-guest inclusion complexes with pharmaceuticals for further development of new drug formulations. The inclusion complex of clomiphene citrate (CL), a poorly water-soluble drug, with native β-cyclodextrin (β-CD) was characterized by a one and two-dimensional nuclear magnetic resonance (NMR) spectros…

  65. 112.

    Okulicz WC, Leavitt WW · Journal of steroid biochemistry · 1988 · PMID 3139938

    The purpose of this study was to compare the biological activity and estrogen receptor (Re) binding affinity of diethylstilbestrol (DES) and estradiol (E2). Uterine weight response and cytosolic progesterone receptor (Rp) induction were equivalent following daily (3 days) injections of DES or E2 to ovariectomized animals. The biological equivalence of DES and E2 was not reflected by competition assays done with either uterine cytosolic or nuclear Re: the relative binding affinity (RBA) of DES to…

  66. 113.

    Sankaran MS, Prasad MR · Indian journal of experimental biology · 1973 · PMID 4783376

  67. 114.

    Nagel S, Baier H, Taubert HD · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 1970 · PMID 4940071

  68. 115.

    Gottardis MM, Ricchio ME, Satyaswaroop PG, Jordan VC · Cancer research · 1990 · PMID 2334915

    Tamoxifen (TAM), a nonsteroidal antiestrogen, is used in the adjuvant treatment of breast cancer. Previous studies, however, have indicated that some human breast and endometrial tumors are stimulated to grow with TAM in the athymic mouse. One such TAM-stimulated tumor is the EnCa101 human endometrial adenocarcinoma. Our aim was to evaluate the ability of different doses of TAM or other nonsteroidal antiestrogens to stimulate the growth of EnCa101 tumors in athymic mice. Additionally we have eva…

  69. 116.

    Sankaran MS, Prasad MR · Journal of reproduction and fertility · 1973 · PMID 4752137

  70. 117.

    Liu W, Zhang L, Chen S, Duan H, et al. · Analytica chimica acta · 2009 · PMID 19046677

    A kind of homemade solid-phase microextraction fibre coupled with gas chromatography-mass spectrometry (GC-MS) was developed for trace analysis of antiestrogens (tamoxifen, cis- and trans-clomiphene) in biological matrices. In this method, derivatization was unnecessary and sample solution could be injected directly after very simple deproteinization operation. The conditions of influencing adsorption of the solid-phase microextraction (SPME) fibre and desorption of the analytes were investigate…

  71. 118.

    Jordan VC, Haldemann B, Allen KE · Endocrinology · 1981 · PMID 6781873

    The estrogenic and antiestrogenic activities of tamoxifen ICI 47,699, enclomiphene, zuclomiphene, and the geometric isomers of monohydroxytamoxifen and CI628 were determined in the 3-day immature rat uterine weight test. Tamoxifen, enclomiphene, and the releated geometric isomers of monohydroxytamoxifen and CI628 were partially estrogenic with antiestrogenic properties. ICI 47,699 and zuclomiphene were predominantly estrogenic; however, an antiestrogen effect for zuclomiphene (100 micrograms dai…

  72. 119.

    Kirchhoff J, Grünke W, Hoffmann B, Nagel W, et al. · Brain research · 1983 · PMID 6661654

    All 8 non-steroidal antiestrogens tested considerably increased progestin receptor concentration in the uterus and, to a lesser extent, in the pituitary of ovariectomized rats. However, the pituitary was more sensitive than the uterus to the estrogen antagonistic action of these compounds, in that monohydroxytamoxifen, LY 117,018, enclomiphene, nitromifen, nafoxidine and trans-tamoxifen completely blocked progestin receptor induction by estradiol benzoate. In these tissues the order of the in vi…

  73. 120.

    Fitzpatrick SL, Berrodin TJ, Jenkins SF, Sindoni DM, et al. · Endocrinology · 1999 · PMID 10465261

    Estrogen is essential in the hypothalamus for the central regulation of reproduction. To understand the molecular mechanism(s) of estrogen action in the hypothalamus, immortalized rat embryonic hypothalamic cell lines were characterized for steroid receptors and subcloned. Scatchard analysis of the D12 subclone demonstrated one high affinity estrogen receptor-binding site (Kd = 31.3+/-1.9 pM) with a Bmax of 30.8+/-0.8 fmol/mg. Estrogen receptor-alpha protein was identified by Western blot and ge…

  74. 121.

    Hiemke C, Ghraf R · Journal of steroid biochemistry · 1984 · PMID 6098784

    The ability of various estrogen antagonists and agonists to compete with [3H]spiroperidol, [3H]domperidone, [3H]dihydroalprenolol, [3H]dihydroergocryptine, [3H]dopamine or [3H]5-hydroxytryptamine for binding to membrane preparations from rat brain tissue was tested. The non-steroidal triphenylethylene-type antiestrogens with an amine side chain--enclomiphene, nitromifene, tamoxifen and zuclomiphene--were found to be competitive inhibitors of [3H]spiroperidol (Kd = 0.12 nM; Bmax = 101 fmol/mg pro…

  75. 122.

    Lee YH, Du JL, Yen FP, Lee CY, et al. · Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology · 2001 · PMID 11399474

    Plasma gonadotropin II (GTH II) concentrations were significantly higher (approx. 15-20-fold) in estradiol-17beta (E(2)) treated (1.0 microg or 2.5 microg g(-1) body weight) female black porgy from days 4 to 12 compared with the control. E(2) (1 microg g(-1) wt.) had a stronger stimulation on plasma GTH II in early recrudescent phase (low GSI) males (11-fold) than in high GSI and late spermiating males (2.6-fold, P< 0.05). No effect of androgens (testosterone, T; 5alpha-dihydrotestosterone, DHT)…

  76. 123.

    Dannies PS, Yen PM, Tashijian AH · Endocrinology · 1977 · PMID 908269

    Established clonal strains of rat pituitary cells, GH-cells, responded prior to 1974 to 10(-11) to 10(-8)M 17beta-estradiol by increasing prolactin synthesis 2-fold and decreasing the production of growth hormone to between 20 and 70% of control values. In experiments in 1975-76, these effects of estradiol were no longer statistically significant. Unexpectedly, the estrogen antagonists enclomiphene, CI-628, tamoxifen, and Lilly 88751 caused increases in both prolactin and growth hormone synthesi…

  77. 124.

    Barrabes A, Duong TH, Combescot C, Lacroix R · Comptes rendus des seances de la Societe de biologie et de ses filiales · 1981 · PMID 6456040

    Within the framework of previous investigations concerning the protective effect of estrogens during an experimental infection with Schistosoma mansoni in female hamster, the respective actions of the cis and trans forms of clomiphene have been studied. These two forms appear to be unable to assure a protective effect, the mean numbers of parasitic worms and the seric specific antibodies levels which have been observed in the treated animals do not significantly differ from those of the control…

  78. 125.
  79. 126.

    Wang H, Chang H, Zhao Y, Wu S, Luo D, Sun D. · 2026 · PMID 41883587

    Obesity is a significant factor affecting male fertility. Infertility in obese men often accompanies with metabolic dysfunction and differs from idiopathic male infertility (MI) in treatment approaches. This scoping review summarizes published treatment options for affecting the semen quality in obese men. A comprehensive literature search strategy was conducted via PubMed, Web of Science, and China National Knowledge Infrastructure. Inclusion criteria encompassed clinical research articles focu…

  80. 127.

    Liberto R, Katlowitz N, Sagalovich D, Davila J. · 2025 · PMID 41080372

    Exogenous testosterone use in men of peak fertility age is a particular concern, as it can lead to disruption of the hypothalamic-pituitary-gonadal (HPG) axis, resulting in infertility. Unfortunately, this population is often unaware of the adverse events, specifically infertility, that can arise from exogenous testosterone use. Discontinuation of exogenous testosterone may result in recovery in the HPG axis with time; however, not all patients will rebound or tolerate symptoms of low testostero…

  81. 128.

    Crosnoe-Shipley LE, Elkelany OO, Rahnema CD, Kim ED. · 2015 · PMID 25949938

    The aim of this study is to review four case-based scenarios regarding the treatment of symptomatic hypogonadism in men. The article is designed as a review of published literature. We conducted a PubMed literature search for the time period of 1989-2014, concentrating on 26 studies investigating the efficacy of various therapeutic options on semen analysis, pregnancy outcomes, time to recovery of spermatogenesis, as well as serum and intratesticular testosterone levels. Our results demonstrated…

  82. 129.

    Lin J, Yuan Y, Huang C, Zi J, Li L, Liu J, Wu X, Li W, Zhao Q, Li Y, Liu Z, Diao A. · 2024 · PMID 39454957

    Autophagy is a conserved eukaryotic cellular clearance and recycling process through the lysosome-mediated degradation of damaged organelles and protein aggregates to maintain homeostasis. Impairment of the autophagy-lysosomal pathway is implicated in the pathogenesis of Alzheimer's disease (AD). Transcription factor EB (TFEB) is a master regulator of autophagy and lysosomal biogenesis. Therefore, activating TFEB and autophagy provides a novel strategy for AD treatment. We previously described t…

  83. 130.

    Hashimi MA, Pinggera GM, Shah R, Agarwal A. · 2025 · PMID 39820213

    <h4>Abstract</h4>Azoospermia, defined as the absence of sperm in the ejaculate, is a well-documented consequence of exogenous testosterone (ET) and anabolic-androgenic steroid (AAS) use. These agents suppress the hypothalamic-pituitary-gonadal (HPG) axis, leading to reduced intratesticular testosterone levels and impaired spermatogenesis. This review examines the pathophysiological mechanisms underlying azoospermia and outlines therapeutic strategies for recovery. Azoospermia is categorized into…

  84. 131.

    Fink J, Ide H, Horie S. · 2024 · PMID 38399562

    Testosterone is crucial in regulating several body functions in men, including metabolic, sexual, and cardiovascular functions, bone and muscle mass, and mental health. Therefore, optimizing testosterone levels in men is an important step to maintaining a healthy body and mind, especially as we age. However, traditional testosterone replacement therapy has been shown to lead to male infertility, caused by negative feedback in the hypothalamic-pituitary-gonadal (HPG) axis. Recent advances in rese…

  85. 132.

    Wu YC, Sung WW. · 2024 · PMID 39338395

    Male hypogonadism, which is characterized by low testosterone levels, has a significant impact on male sexual function, overall health, and fertility. Testosterone replacement therapy (TRT) is the conventional treatment for this condition, but it has potential adverse effects and is not suitable for men seeking to conceive. Testosterone plays an essential role in male sexual function, metabolism, mood, and overall well-being. Clomiphene citrate, a drug originally developed for female infertility…

  86. 133.

    Shukla J, Moni SN, Hasan MM, Islam MA, Shikha AN, Jahan NW, Ishrat S. · 2025 · PMID 40899280

    <h4>Objective</h4>The aim of this study was to observe the effect of clomiphene citrate on sperm parameters in infertile men diagnosed with idiopathic oligoasthenozoospermia.<h4>Methods</h4>This randomized controlled trial involved 50 infertile men diagnosed with idiopathic oligoasthenozoospermia, all of whom had normal serum testosterone and follicle-stimulating hormone levels. The participants were divided into two groups. The first group (n=25) received a daily dose of 50 mg of clomiphene cit…

  87. 134.

    Blazewicz A, Poplawska M, Daniszewska B, Piorunska K, Karynski M. · 2025 · PMID 40177353

    <h4>Background</h4>The term post-cycle therapy (PCT) often appears in bodybuilding forums in the context of anabolic-androgenic steroids (AAS) cessation. To reduce the negative impact of AAS on the hormonal system, unapproved PCT is used, which consist of medications that help restore hormonal balance. The most used medicinal products are selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and preparations containing human chorionic gonadotropin (hCG). These substances ar…

  88. 135.

    Gupta S, Satwik R, Majumdar A, Mittal S, Tiwari N. · 2015 · PMID 26538856

    <h4>Objective</h4>This study was conducted to compare an extended clomiphene-based ovarian stimulation regimen with the conventional antagonist protocol in donor-recipient cycles.<h4>Materials and methods</h4>A total of 170 (N) donors were stimulated between January 2013 and December 2013. Conventional antagonist protocol (group I) was employed in (n1 = 31) cycles, and clomiphene was used in (n2 = 139) donor cycles (group II). 50 mg clomiphene was given simultaneously with gonadotropins from day…

  89. 136.

    Flores JM, Salter CA, Mulhall JP. · 2023 · PMID 37122109

  90. 137.

    Patel AS, Leong JY, Ramos L, Ramasamy R. · 2019 · PMID 30350483

    Testosterone has a variety of functions and is commonly used in older men to treat symptoms of hypogonadism, such as decreased libido, decreased mood and erectile dysfunction. Despite its positive effects on sexual function, it has a negative effect on fertility. Exogenous testosterone therapy can negatively affect the hypothalamic-pituitary gonadal axis and inhibit the production of follicle stimulating hormone and luteinizing hormone. The purpose of this review is to discuss the contraceptive…

  91. 138.

    Desai A, Yassin M, Cayetano A, Tharakan T, Jayasena CN, Minhas S. · 2022 · PMID 35783920

    Use of testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS) has increased over the last 20 years, coinciding with an increase in men presenting with infertility and hypogonadism. Both agents have a detrimental effect on spermatogenesis and pose a clinical challenge in the setting of hypogonadism and infertility. Adding to this challenge is the paucity of data describing recovery of spermatogenesis on stopping such agents. The unwanted systemic side effects of these agent…

  92. 139.

    Chin PY, Chan HY, Kieffer TEC, Prins JR, Russell DL, Davies MJ, Robertson SA. · 2024 · PMID 38608138

    Clomiphene citrate is a common treatment for ovulation induction in subfertile women, but its use is associated with elevated risk of adverse perinatal outcomes and birth defects. To investigate the biological plausibility of a causal relationship, this study investigated the consequences in mice for fetal development and pregnancy outcome of periconception clomiphene citrate administration at doses approximating human exposures. A dose-dependent adverse effect of clomiphene citrate given twice…

  93. 140.

    Khourdaji I, Lee H, Smith RP. · 2018 · PMID 30159242

    For a significant number of couples worldwide, infertility is a harsh reality. As specialists in male infertility, much of our armamentarium lacks definitive, evidence-based therapies. For years, we have relied on manipulation of the male hormonal axis to treat those men who help carry the burden of infertility in their partnerships. Indeed, male factor infertility is the sole component of infertility in at least 20% of couples. Further compounding this dilemma is that 25% to 50% of males with i…

  94. 141.
  95. 142.

    Ramasamy R, Armstrong JM, Lipshultz LI. · 2015 · PMID 25337850

    An increasing number of young and middle-aged men are seeking treatment for symptoms related to deficient levels of androgens (hypogonadism) including depression, loss of libido, erectile dysfunction, and fatigue. The increase in prevalence of testosterone supplementation in general and anabolic steroid-induced hypogonadism specifically among younger athletes is creating a population of young men who are uniquely impacted by the testicular end-organ negative consequences of exogenous steroid use…

  96. 143.

    Abdul Hamid F, Abu MA, Abdul Karim AK, Ahmad MF, Abd Aziz NH, Mohd Kamal DA, Mokhtar MH. · 2022 · PMID 35885010

    Polycystic ovary syndrome (PCOS) and endometriosis are reproductive disorders that may cause infertility. The pathology of both diseases has been suggested to be associated with sex steroid hormone receptors, including oestrogen receptors (ER), progesterone receptors (PRs) and androgen receptors (ARs). Therefore, with this review, we aim to provide an update on the available knowledge of these receptors and how their interactions contribute to the pathogenesis of PCOS and endometriosis. One of t…

  97. 144.

    Khan FN, Qazi S, Tanveer K, Raza K. · 2017 · PMID 29208326

    Ebola virus (EBOV), a member of Filoviridae virus family under the genus Ebolavirus, has emerged as a dangerous and potential threat to human health globally. It causes a severe and deadly hemorrhagic fever in humans and other mammals, called Ebola Virus Disease (EVD). In recent outbreaks of EVD, there has been loss of large numbers of individual's life. Therefore, EBOV has attracted researchers and increased interests in developing new models for virus evolution, and therapies. The EBOV interac…

  98. 145.

    Ramasamy R, Scovell JM, Lipshultz LI. · 2015 · PMID 26594652

  99. 146.

    Stahl F, Denner P, Piston D, Evert BO, de Boni L, Schmitt I, Breuer P, Wüllner U. · 2021 · PMID 34615900

    Multiplications, mutations and dysregulation of the alpha synuclein gene (SNCA) are associated with the demise of dopaminergic neurons and are considered to play important roles in the pathogenesis of familial and sporadic forms of Parkinson's disease. Regulation of SNCA expression might thus be an appropriate target for treatment. We aimed to identify specific modulators of SNCA transcription, generated CRISPR/Cas9 modified SNCA-GFP-luciferase (LUC) genomic fusion- and control cell lines and sc…

  100. 147.

    2014

    Surging interest in addressing male hypogonadism in recent years has resulted in the identification and development of novel pharmacotherapeutic approaches that may yield increased serum testosterone levels. Testosterone replacement therapy is controversial with concerns surrounding its proper indications and potential side effects. However, interest remains strong to explore treatment options that may address the signs and symptoms of male hypogonadism. Several testosterone preparations are com…

  101. 148.

    Sawant S, Bhide P. · 2019 · PMID 31908561

    Polycystic ovary syndrome is the most common endocrinological disorder in women of reproductive age. It is commonly associated with anovulatory subfertility, for which there are a range of treatment options available to help them conceive. These options are given in a step-wise manner with an appropriate selection of patients to maximise success rates with minimal complications. This review discusses the importance and involvement of multidisciplinary care when offering treatment to women with s…

  102. 149.

    DiGiorgio L, Sadeghi-Nejad H. · 2016 · PMID 28078215

    The incidence of hypogonadism has been steadily increasing over the last few years. Exogenous testosterone has been the standard treatment for hypogonadal men, but is associated with suppression of spermatogenesis as well as other possible adverse effects. There are other medications, currently considered "off label" for androgen replenishment, that exert their effect through modulation of the hypothalamic-gonadal axis. These medications increase endogenous testosterone levels and offer a differ…

  103. 150.

    VAN AS ANDREW. · 2012

    The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene.

  104. 151.

    VAN AS ANDRE. · 2010

    The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene. The invention is also directed to methods for the prevention and treatment of diabetes mellitus type 2.

  105. 152.

    Francisco R, Jaroudi S, Murtaza Ali M, Frost J, Chemitiganti R, Peiris AN. · 2019 · PMID 30956589

    Male hypogonadism is associated with poor sexual function. Testosterone therapy via the intramuscular route is the preferred treatment but is associated with secondary polycythemia. We report a patient in whom clomiphene citrate improved hypogonadal symptoms and restored normal free testosterone levels. Clomiphene is inexpensive and can be given orally in secondary hypogonadism. Clomiphene citrate is a promising alternative in patients who develop secondary polycythemia with testosterone.

Case Reports

1
  1. 153.

    Tariq MN, Abdel Halim AT, Evans JA · Cureus · 2026 · PMID 42741668

    Enclomiphene citrate is increasingly prescribed off-label for secondary male hypogonadism, and its cardiovascular safety profile remains poorly characterised. We report a 46-year-old man with a mitral valve repair performed 20 years earlier and chronic immune thrombocytopenia (ITP) in whom atrial flutter was first documented shortly after he inadvertently increased his enclomiphene dose, taking 50 mg daily in place of 25 mg daily. Laboratory evaluation demonstrated chronic thrombocytopenia with…

Curated sources on file

5
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.

Continue reading